The NIHR Moorfields Biomedical Research Centre (BRC) is a partnership between Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology.
Our first BRC was established in April 2007 and lasted five years. Following open competition, we were awarded new funding for a BRC to operate from April 2012 to March 2017. The centre is funded by the Department of Health and is part of the National Institute for Health Research. Its purpose is to conduct 'translational research' that is designed to take advances in basic medical research from the laboratory to the clinic, enabling patients to benefit more quickly from new scientific breakthroughs.
Our centre is one of 11 national Biomedical Research Centres and is the only one dedicated to eye disease.
Moorfields Eye Hospital NHS Foundation Trust
Moorfields Eye Hospital, the largest specialist eye hospital in the UK, has been providing eye care and treatment to the community for over 200 years.
During this time the hospital has developed a unique reputation for high-quality and expert patient care, as well as outstanding and groundbreaking research into eye disease and therapeutic interventions. In 2009/10 we recorded more than 330,000 outpatient attendances in our clinics and almost 70,000 attendances at our specialist Accident & Emergency Department. Over 27,000 in-patient and day case procedures were performed, and around 8,500 laser treatments were carried out.
UCL Institute of Ophthalmology
The UCL Institute of Ophthalmology attracts researchers of the highest international calibre, exploring fundamental and applied questions in the science of vision.
The mission of the UCL Institute of Ophthalmology is to develop new treatments for eye disease out of a large and varied foundation of basic research. The UCL Institute of Ophthalmology is also part of UCL Biomedicine, one of the largest aggregates of biomedical expertise in the world.
The range of diseases we study extends from inherited retinal degenerations affecting young children to age-related macular degeneration and glaucoma, the most common causes of blindness in the elderly. Currently we have groups investigating every stage of the visual process from the mechanics of rods and cones to the brain’s interpretation of complex visual scenes. Our researchers are making progress in understanding the basic mechanisms of blinding disease and investigating new methods of treatment by conventional pharmacology, gene therapy and cellular therapy, including stem cells.
Our joint site has the highest measure of scientific productivity and impact in the world for ophthalmic research activity. We continue to build a strong team of academic, research and clinical colleagues, to explore different ways of finding better treatments, and to help our patients access new procedures and treatments as quickly and safely as possible.